I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

Viking Therapeutics TodayVKTXViking Therapeutics$22.98 -0.13 (-0.55%) 52-Week Range$18.92▼$81.86Price Target$89.75Add to WatchlistViking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024. But it’s been a steady move lower. As of the market close on April 15, 2025, the stock is within 10% of that January 2024 close. This week alone has been wild. Viking stock shot up approximately 12% ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly 3 months since my last Viking Therapeutics, Inc. (NASDAQ: VKTX ) article , where I discussed how VKTX had dropped 50% despite strong clinical progress in obesity and NASH due to broader concerns in theHe is the leader of the investing ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (VKTX -2.18%), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off.Nevertheless, the company's prospects remain positive with its portfolio of therapeutic candidates covering metabolic and endocrine diseases ...

Viking Therapeutics, Inc. VKTX,  Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.Pfizer Inc. PFE announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.Also Read ...

Viking Therapeutics (VKTX 15.16%) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects.This year, however, has been a much different story, with the markets on shaky ground. Viking has lost more than 40% of its value since January.While there has been some significant volatility in the short term, there could still be a lot more room for Viking to be a much more valuable business in the long run, especially if it ...

Viking Therapeutics (VKTX -0.99%) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15 to surpass $100 billion later this decade. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying injectable and oral formulations of VK2735 in clinical trials, and results so far have been impressive. As for stock performance, Viking won there too in the early part of ...

Investors will be eagerly watching for the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.34, showcasing a 30.77% downward movement from the corresponding quarter of the prior year. Viking Therapeutics, Inc. (VKTX) closed the latest trading day at $23.91, indicating a -0.99% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.38%. Meanwhile, the Dow experienced a drop of 0.03%, ...

文章核心观点 - 维京治疗公司完成口服肥胖药物VK2735 II期研究受试者招募，若药物有效安全将有商业潜力，但公司面临肥胖药物市场激烈竞争 [1][3] 公司进展 - 维京治疗公司完成VENTURE - 口服给药II期研究受试者招募，预计2025年下半年出数据 [1] - 该研究招募约280名肥胖或超重且有至少一种体重相关合并症的成年人，随机分入六个药物剂量组或安慰剂组，主要终点是治疗13周后体重较基线的百分比变化 [2] - 早期研究数据显示口服VK2735患者28天每日给药后体重最多减轻8.2%，安慰剂组为1.4%，公司认为延长治疗时间或进一步减轻体重 [4] - 公司重申今年上半年启动VK2735皮下注射剂后期研究的计划 [5] 公司股价表现 - 年初至今公司股价暴跌36%，而行业增长1% [6] 行业竞争情况 - 肥胖市场受关注，礼来和诺和诺德主导市场，美国肥胖市场预计2030年达1000亿美元，多家公司正快速研发肥胖药物 [8][9] - 罗氏去年27亿美元收购卡莫特疗法公司进入肥胖市场，增加肠促胰岛素产品组合，CT - 388正在进行中期研究，本月还与西兰制药达成合作协议 [10][11] - 安进11月公布肥胖药物MariTide II期研究52周顶线数据，平均减重约20%，计划开展广泛III期项目 [12] - 默克和艾伯维通过授权协议进入肥胖市场，艾伯维与丹麦公司合作，默克获得中国药企口服减肥药授权 [13] 公司评级 - 维京治疗公司目前Zacks评级为3（持有） [14]

文章核心观点 - 维京治疗公司宣布其口服片剂VK2735的2期临床试验完成受试者招募，预计2025年下半年公布研究数据，此前该药物的1期和皮下注射2期试验均取得积极结果，公司还有多个在研项目 [1][3][5] 公司进展 - 公司完成口服片剂VK2735的2期临床试验受试者招募，预计2025年下半年公布数据 [1] - 2期VENTURE - 口服给药试验是随机、双盲、安慰剂对照的多中心研究，约280名成人入组，随机分配到6个给药组或安慰剂组，主要终点是治疗13周后体重的百分比变化 [2] - 公司计划于2025年上半年启动VK2735皮下注射制剂的3期开发 [5] 过往试验结果 - VK2735片剂在健康志愿者的28天1期多次递增剂量临床试验中，服用者平均体重较基线有剂量依赖性降低，最高达8.2%，随访至第57天体重减轻效果持续，最高达8.3%，28天后最多100%的受试者体重减轻≥5%，而安慰剂组为0% [3] - 多次递增剂量试验中，口服VK2735每日一次给药28天，剂量高达100mg时，显示出良好的安全性和耐受性，99%的治疗突发不良事件为轻度或中度，90%为轻度，胃肠道不良事件也多为轻度或中度 [4] - 皮下注射VK2735的2期VENTURE研究取得积极数据，达到主要和所有次要终点，服用者平均体重较基线显著降低，最高达14.7%，从第1周开始各剂量组与安慰剂组有显著差异，且13周内体重减轻呈渐进性，未出现平台期，安全性和耐受性良好 [5] 公司其他在研项目 - 公司正在开发VK2809，用于治疗脂质和代谢紊乱，在非酒精性脂肪性肝炎和纤维化的2b期研究中达到主要和次要终点，在非酒精性脂肪性肝病和LDL - C升高的2a期试验中，服用者LDL - C和肝脏脂肪含量较安慰剂组显著降低 [8] - 公司正在评估一系列内部开发的双胰淀素和降钙素受体激动剂用于治疗肥胖和其他代谢紊乱 [8] - 公司正在开发VK0214，用于治疗X - 连锁肾上腺脑白质营养不良，在1b期临床试验中显示出安全性和耐受性良好，与安慰剂组相比，血浆中极长链脂肪酸和其他脂质水平显著降低 [8] 行业背景 - 激活胰高血糖素样肽1（GLP - 1）受体可降低血糖、减少食欲、减轻体重和提高胰岛素敏感性，司美格鲁肽是已获美国食品药品监督管理局批准的GLP - 1受体激动剂 [6] - 研究探索共同激活葡萄糖依赖性促胰岛素多肽（GIP）受体以增强GLP - 1受体激活的治疗益处，替尔泊肽是已获批的双GLP - 1/GIP受体激动剂 [7]